# Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

> **NCT06705608** · — · COMPLETED · sponsor: **University of British Columbia** · enrollment: 4000 (estimated)

## Conditions studied

- Multiple Sclerosis
- Skin Cancer
- Skin Cancer Melanoma
- Skin Cancers - Basal Cell Carcinoma
- Skin Cancer, Squamous Cell
- Multiple Sclerosis (MS) - Relapsing-remitting

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Natalizumab
- **DRUG:** Dimethyl fumarate (DMF)
- **DRUG:** Alemtuzumab
- **DRUG:** Teriflunomide

## Key facts

- **NCT ID:** NCT06705608
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705608, "Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06705608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*